{"id":40019,"date":"2025-08-25T14:54:04","date_gmt":"2025-08-25T06:54:04","guid":{"rendered":"https:\/\/flcube.com\/?p=40019"},"modified":"2025-08-25T14:54:05","modified_gmt":"2025-08-25T06:54:05","slug":"remegen-reports-48-revenue-growth-in-2025-h1-driven-by-telitacicept-and-disitamab-vedotin","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40019","title":{"rendered":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin"},"content":{"rendered":"\n<p>RemeGen Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688331:SHA\">SHA: 688331<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.<\/p>\n\n\n\n<p><strong>Revenue Drivers<\/strong><br>The growth was primarily driven by increased sales of telitacicept (RC18), a dual-target fusion protein for moderate-to-severe systemic lupus erythematosus (SLE) and rheumatoid arthritis, and disitamab vedotin (RC48), a HER2 antibody-drug conjugate (ADC) for urothelial carcinoma and gastric cancer. In May 2025, telitacicept received additional approval for adult generalized myasthenia gravis, while disitamab vedotin was approved for advanced breast cancer with HER2-positive status and liver metastases. An additional application for HER2-low expressing breast cancer was also submitted to the NMPA.<\/p>\n\n\n\n<p><strong>Commercialization Teams<\/strong><br>As of June 30, 2025, RemeGen&#8217;s autoimmune commercialization team had approximately 900 sales personnel, and its oncology team exceeded 500 members. Both teams completed drug access in over 1,000 hospitals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688331_20250823_SIFJ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688331_20250823_SIFJ.\"><\/object><a id=\"wp-block-file--media-744f2405-dce7-48fb-add0-17c1ef2b15d7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688331_20250823_SIFJ.pdf\">688331_20250823_SIFJ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688331_20250823_SIFJ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-744f2405-dce7-48fb-add0-17c1ef2b15d7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40021,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,27,1155,375,1294],"class_list":["post-40019","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-finanical-reports","tag-hkg-9995","tag-remegen","tag-sha-688331"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40019\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin\" \/>\n<meta property=\"og:description\" content=\"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40019\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T06:54:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-25T06:54:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin\",\"datePublished\":\"2025-08-25T06:54:04+00:00\",\"dateModified\":\"2025-08-25T06:54:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2507.webp\",\"keywords\":[\"Biotech\",\"Finanical Reports\",\"HKG: 9995\",\"RemeGen\",\"SHA: 688331\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40019#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40019\",\"name\":\"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2507.webp\",\"datePublished\":\"2025-08-25T06:54:04+00:00\",\"dateModified\":\"2025-08-25T06:54:05+00:00\",\"description\":\"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40019\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2507.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2507.webp\",\"width\":1080,\"height\":608,\"caption\":\"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40019#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry","description":"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40019","og_locale":"en_US","og_type":"article","og_title":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin","og_description":"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.","og_url":"https:\/\/flcube.com\/?p=40019","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-25T06:54:04+00:00","article_modified_time":"2025-08-25T06:54:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40019#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40019"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin","datePublished":"2025-08-25T06:54:04+00:00","dateModified":"2025-08-25T06:54:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40019"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40019#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp","keywords":["Biotech","Finanical Reports","HKG: 9995","RemeGen","SHA: 688331"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40019#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40019","url":"https:\/\/flcube.com\/?p=40019","name":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40019#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40019#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp","datePublished":"2025-08-25T06:54:04+00:00","dateModified":"2025-08-25T06:54:05+00:00","description":"RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual results, achieving a revenue of RMB 1.098 billion, marking a 48.02% year-on-year (YOY) increase. The net loss attributable to the parent company narrowed by 42.40% YOY to RMB 450 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40019#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40019"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40019#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp","width":1080,"height":608,"caption":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40019#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2507.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40019"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40019\/revisions"}],"predecessor-version":[{"id":40022,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40019\/revisions\/40022"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40021"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}